Hotsia.Com : เที่ยวสะใจ

The Chronic Kidney Disease Solution™ By Shelly Manning It is an eBook that includes the most popular methods to care and manage kidney diseases by following the information provided in it. This easily readable eBook covers up various important topics like what is chronic kidney disease, how it is caused, how it can be diagnosed, tissue damages caused by chronic inflammation, how your condition is affected by gut biome, choices for powerful lifestyle and chronic kidney disease with natural tools etc.

---

Hyperphosphatemia and CKD

Hyperphosphatemia, or elevated levels of phosphate in the blood, is a common and serious complication in patients with Chronic Kidney Disease (CKD). As kidney function declines, the kidneys lose their ability to excrete phosphate, leading to its accumulation in the blood. Hyperphosphatemia contributes to a variety of adverse effects, including disturbances in bone metabolism, vascular calcification, and an increased risk of cardiovascular disease, which is the leading cause of death in CKD patients. Proper management of phosphate levels is a key component of treating CKD and its complications.

Epidemiology of Hyperphosphatemia in CKD

• Prevalence: Hyperphosphatemia is uncommon in early-stage CKD (stages 1 and 2) but becomes more prevalent as CKD progresses to stages 3–5. It is especially prevalent in patients with end-stage renal disease (ESRD) who are on dialysis. Approximately 50–75% of ESRD patients develop hyperphosphatemia.
• Onset: Phosphate levels often start to rise when the glomerular filtration rate (GFR) falls below 30 mL/min/1.73 m² (stage 4 CKD), as the kidneys lose their ability to maintain phosphate homeostasis.

Phosphate Homeostasis and the Role of the Kidneys

Phosphate is an essential mineral involved in several critical biological processes, including bone mineralization, energy metabolism (as part of ATP), and cell signaling. The kidneys play a crucial role in maintaining phosphate balance by regulating phosphate reabsorption and excretion.

1. Dietary Phosphate Intake: Phosphate is absorbed in the intestines from dietary sources, primarily animal products such as meat, dairy, eggs, and processed foods with added phosphate.
2. Renal Excretion: Under normal conditions, about 85% of filtered phosphate is reabsorbed in the proximal tubules of the kidneys, and the remaining 15% is excreted in the urine. This reabsorption process is regulated by various factors, including parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), both of which promote phosphate excretion (phosphaturia) in response to elevated phosphate levels.
3. Phosphate Regulation: Phosphate levels are tightly regulated by a balance between intestinal absorption, bone storage, and renal excretion. The major hormones involved in phosphate homeostasis include:
   • PTH: Increases phosphate excretion by the kidneys and stimulates the release of calcium from bones.
   • FGF23: Produced by osteocytes in response to high phosphate levels, FGF23 inhibits phosphate reabsorption in the kidneys and suppresses the production of calcitriol (active vitamin D).
   • Vitamin D (Calcitriol): Promotes intestinal absorption of calcium and phosphate and increases phosphate reabsorption in the kidneys.

Pathophysiology of Hyperphosphatemia in CKD

As kidney function declines, phosphate homeostasis becomes disrupted, leading to phosphate retention and hyperphosphatemia. Several key factors contribute to the development of hyperphosphatemia in CKD patients:

1. Reduced Renal Phosphate Excretion:

In CKD, the kidneys’ ability to excrete phosphate diminishes as GFR declines. When the GFR falls below 30 mL/min, phosphate excretion is insufficient to balance dietary intake, leading to phosphate accumulation in the blood. This is a primary mechanism behind hyperphosphatemia in CKD.

2. Elevated Parathyroid Hormone (PTH):

Hyperphosphatemia stimulates the release of PTH from the parathyroid glands, resulting in secondary hyperparathyroidism. Elevated PTH increases calcium reabsorption in the kidneys, increases phosphate excretion, and promotes the release of calcium and phosphate from bones (bone resorption). However, as CKD progresses, the kidneys become less responsive to PTH, and phosphate excretion remains inadequate.

3. Fibroblast Growth Factor 23 (FGF23):

FGF23 levels rise early in CKD as a compensatory response to phosphate retention. FGF23 increases phosphate excretion and suppresses the production of calcitriol, reducing intestinal absorption of phosphate. While this response helps to initially mitigate phosphate accumulation, its effects diminish as kidney function declines further. High levels of FGF23 are also associated with left ventricular hypertrophy and increased cardiovascular mortality in CKD patients.

4. Vitamin D Deficiency:

As CKD progresses, the kidneys lose their ability to convert inactive vitamin D (25-hydroxyvitamin D) into its active form, 1,25-dihydroxyvitamin D (calcitriol). Low calcitriol levels reduce the intestinal absorption of calcium, leading to hypocalcemia and further stimulation of PTH secretion. This state of secondary hyperparathyroidism exacerbates the release of phosphate from bones, contributing to hyperphosphatemia.

5. Bone and Mineral Disorders:

Hyperphosphatemia is a major component of CKD-Mineral and Bone Disorder (CKD-MBD), a systemic disorder characterized by abnormalities in calcium, phosphate, PTH, and vitamin D metabolism. CKD-MBD leads to bone diseases such as osteitis fibrosa cystica (high bone turnover due to secondary hyperparathyroidism) and adynamic bone disease (low bone turnover). Bone resorption caused by elevated PTH contributes to increased phosphate release into the bloodstream.

Clinical Consequences of Hyperphosphatemia in CKD

Hyperphosphatemia in CKD patients has far-reaching clinical consequences, particularly on the cardiovascular system, bones, and overall mortality.

1. Vascular Calcification:

• One of the most serious complications of hyperphosphatemia is vascular calcification, where calcium and phosphate are deposited in the walls of blood vessels. This process is driven by elevated phosphate levels, which promote the differentiation of vascular smooth muscle cells into osteoblast-like cells that deposit calcium.
• Vascular calcification increases arterial stiffness, leading to hypertension, left ventricular hypertrophy (LVH), and an elevated risk of cardiovascular disease (CVD). Calcification of coronary arteries and aortic valves contributes to an increased risk of myocardial infarction, heart failure, and sudden cardiac death in CKD patients.
• Hyperphosphatemia-induced vascular calcification is a major contributor to the high cardiovascular mortality seen in CKD patients, particularly those on dialysis.

2. Bone Disease (Renal Osteodystrophy):

• Hyperphosphatemia contributes to bone disorders in CKD, collectively known as renal osteodystrophy. High phosphate levels stimulate PTH secretion, leading to excessive bone resorption and the development of osteitis fibrosa cystica, characterized by bone pain, fractures, and skeletal deformities.
• In some CKD patients, aggressive treatment of hyperphosphatemia can lead to adynamic bone disease, where bone turnover is abnormally low, resulting in brittle bones and an increased risk of fractures.

3. Soft Tissue Calcification:

• Hyperphosphatemia can lead to calcification of soft tissues, including the skin, muscles, lungs, and joints. This condition can cause calciphylaxis, a rare but life-threatening disorder characterized by painful skin ulcers, tissue necrosis, and a high risk of sepsis and death.

4. Increased Mortality:

• Elevated serum phosphate levels are strongly associated with increased all-cause mortality in CKD patients. Studies have shown that even modest increases in serum phosphate levels (above 4.5 mg/dL) are associated with a higher risk of death, primarily from cardiovascular causes.

Diagnosis of Hyperphosphatemia in CKD

Diagnosis of hyperphosphatemia in CKD involves routine monitoring of serum phosphate levels, as well as other related markers of bone and mineral metabolism.

1. Serum Phosphate Levels:
   • Serum phosphate levels should be measured regularly in CKD patients, particularly in those with stage 4-5 CKD or ESRD. Normal phosphate levels are typically 2.5–4.5 mg/dL, and levels above 4.5 mg/dL are considered elevated.
2. Serum Calcium and PTH:
   • Serum calcium and intact PTH levels should also be measured to assess for secondary hyperparathyroidism and disturbances in calcium-phosphate balance. Low serum calcium and elevated PTH are common in hyperphosphatemia.
3. Serum FGF23 and Vitamin D:
   • Measurement of FGF23 levels can provide insights into phosphate metabolism, especially in the early stages of CKD. Vitamin D (25-hydroxyvitamin D and 1,25-dihydroxyvitamin D) levels should be monitored to assess for vitamin D deficiency and guide treatment with vitamin D supplements.
4. Imaging Studies:
   • Imaging techniques such as X-rays, CT scans, or ultrasound may be used to detect vascular calcification in CKD patients with hyperphosphatemia.

Management of Hyperphosphatemia in CKD

The management of hyperphosphatemia in CKD involves dietary interventions, phosphate binders, vitamin D supplementation, and control of secondary hyperparathyroidism.

1. Dietary Phosphate Restriction:

• Dietary phosphate restriction is a cornerstone of hyperphosphatemia management. CKD patients are advised to limit intake of phosphate-rich foods such as dairy products, meat, fish, eggs, and processed foods with phosphate additives.
• A renal dietitian can help guide patients in choosing lower-phosphate alternatives while ensuring adequate nutrition. The recommended daily intake of phosphate is typically 800–1,000 mg for CKD patients.

2. Phosphate Binders:

• Phosphate binders are used to reduce phosphate absorption from the gastrointestinal tract by binding phosphate in the gut and excreting it in the stool. Common types of phosphate binders include:
  • Calcium-based binders: Such as calcium carbonate or calcium acetate. These binders are effective but can contribute to hypercalcemia and vascular calcification if overused.
  • Non-calcium-based binders: Such as sevelamer and lanthanum carbonate. These are preferred in patients at risk of hypercalcemia or vascular calcification.
  • Iron-based binders: Such as sucroferric oxyhydroxide and ferric citrate, which also help manage anemia in CKD patients by increasing iron levels.

3. Vitamin D Supplementation:

• Vitamin D analogs (such as calcitriol or paricalcitol) are used to correct vitamin D deficiency, increase intestinal calcium absorption, and suppress PTH secretion. Careful dosing is required to avoid hypercalcemia and further phosphate retention.

4. Management of Secondary Hyperparathyroidism:

• Calcimimetics (such as cinacalcet) are medications that enhance the sensitivity of the parathyroid glands to calcium, reducing PTH secretion and lowering phosphate and calcium levels. Calcimimetics are especially useful in patients with severe secondary hyperparathyroidism or those who do not respond to vitamin D therapy.

5. Dialysis:

• In patients with ESRD, dialysis is necessary to remove excess phosphate from the blood. However, dialysis alone is often insufficient to control hyperphosphatemia, and phosphate binders are typically needed in conjunction with dialysis.

Prognosis and Complications

Hyperphosphatemia is associated with an increased risk of cardiovascular complications, bone disease, and mortality in CKD patients. Effective management of hyperphosphatemia can slow the progression of vascular calcification, reduce the risk of cardiovascular events, and improve long-term outcomes.

Conclusion

Hyperphosphatemia is a common and significant complication of CKD that contributes to bone and mineral disorders, vascular calcification, and increased cardiovascular risk. As kidney function declines, the body’s ability to excrete phosphate diminishes, leading to its accumulation in the blood. Early identification and management of hyperphosphatemia are essential to improving outcomes in CKD patients. Dietary phosphate restriction, the use of phosphate binders, and the management of secondary hyperparathyroidism are key strategies to control phosphate levels and prevent complications. A multidisciplinary approach involving nephrologists, dietitians, and other healthcare providers is essential for optimizing the management of hyperphosphatemia in CKD patients.

The Chronic Kidney Disease Solution™ By Shelly Manning It is an eBook that includes the most popular methods to care and manage kidney diseases by following the information provided in it. This easily readable eBook covers up various important topics like what is chronic kidney disease, how it is caused, how it can be diagnosed, tissue damages caused by chronic inflammation, how your condition is affected by gut biome, choices for powerful lifestyle and chronic kidney disease with natural tools etc.

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. I share my experiences on www.hotsia.com